دورية أكاديمية
Exploring Definitions and Predictors of Severe Asthma Clinical Remission Post-Biologic in Adults.
| العنوان: | Exploring Definitions and Predictors of Severe Asthma Clinical Remission Post-Biologic in Adults. |
|---|---|
| المؤلفون: | Perez-de-Llano L; Hospital Universitario Lucus Augusti, 309716, Lugo, Galicia, Spain., Scelo G; Observational and Pragmatic Research Institute, Singapore, Singapore, Singapore.; Optimum Patient Care Global, Cambridge, United Kingdom of Great Britain and Northern Ireland., Tran TN; AstraZeneca, Gaithersburg, Maryland, United States., Le TT; AstraZeneca R&D Gaithersburg, 468090, Gaithersburg, Maryland, United States., Fagerås M; AstraZeneca, Gothenburg, Sweden., Cosio BG; Hospital Universitari Son Espases, 375118, IdISBa and Respiratory Medicine, Palma de Mallorca, Spain.; Ciber Enfermedades Respiratorias (Ciberes), Madrid, Spain., Peters M; Concord Hospital, Department of Thoracic Medicine, Sydney, Australia., Pfeffer PE; Queen Mary University of London, 4617, William Harvey Research Institute, London, United Kingdom of Great Britain and Northern Ireland., Al-Ahmad M; Kuwait University, Al-Rashed Allergy Center, Ministry of Health, Microbiology Department, College of Medicine, Kuwait , Kuwait., Al-Lehebi RO; King Fahad Medical City, 37849, Department of Pulmonology,, Riyadh, Saudi Arabia.; Alfaisal University, 101686, Riyadh, Saudi Arabia., Altraja A; University of Tartu and Lung Clinic, Tartu University Hospital, Department of Pulmonology, Tartu, Estonia., Bergeron C; Vancouver General Hospital, 8167, Vancouver, British Columbia, Canada.; The University of British Columbia, 8166, Vancouver, British Columbia, Canada., Bjermer LH; Skåne University Hospital Labmedicin Skane, 405121, Respiratory Medicine and Allergology, Lund, Skåne, Sweden., Bjerrum AS; Aarhus Universitetshospital, 11297, Department of Respiratory Medicine, Aarhus, Denmark., Bulathsinhala L; Observational and Pragmatic Research Institute Pte Ltd, 614173, Singapore, Singapore.; Optimum Patient Care UK, 601419, Cambridge, England, United Kingdom of Great Britain and Northern Ireland., Busby J; Queen's University Belfast, Centre of Experimental Medicine, Belfast, United Kingdom of Great Britain and Northern Ireland., Cano Rosales DJ; Instituto Neumológico del Oriente, Bucaramanga, Colombia., Canonica GW; IRCCS Humanitas Research Hospital, 9268, Personalized Medicine, Asthma and Allergy, Rozzano, Lombardia, Italy.; Humanitas University, 437807, Department of Biomedical Sciences, Milan, Italy., Carter VA; Optimum Patient Care, Cambridge, United Kingdom of Great Britain and Northern Ireland.; Observational and Pragmatic Research Institute, Singapore, Singapore., Charriot J; PhyMedExp, Univ Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France., Christoff GC; Medical University, Bulgaria , Sofia, Bulgaria., Denton EJ; Alfred Health, Melbourne, Australia., Dorscheid DR; University of British Columbia, Vancouver, British Columbia, Canada., Fernandez Sanchez MJ; Hospital Universitario San Ignacio, 173049, Pulmonary Unit, Bogota, Colombia.; Pontificia Universidad Javeriana, 27964, Faculty of Medicine, Bogota, Colombia., Fonseca JA; Faculty of Medicine, University of Porto, CINTESIS, Porto, Portugal.; CUF Porto, Allergy Department, Senhora da Hora, Portugal., Gibson PG; University of Newcastle, 5982, Callaghan, New South Wales, Australia., Goh CYY; Observational and Pragmatic Research Institute Pte Ltd, 614173, Singapore, Singapore., Heaney LG; Belfast City Hospital, Regional Respiratory Centre, Belfast, United Kingdom of Great Britain and Northern Ireland., Heffler E; Universita degli Studi di Catania, 9298, Clinical and Experimental Medicie, Catania, Italy., Hew M; Alfred Hospital, 5390, Allergy, Asthma & Clinical Immunology, Melbourne, Victoria, Australia.; Monash University Faculty of Medicine Nursing and Health Sciences, 22457, School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia., Iwanaga T; Kindai University Hospital, 326473, Osakasayama, Osaka, Japan., Katial R; AstraZeneca US, 33366, BioPharmaceuticals Medical, Gaithersburg, Maryland, United States., Koh MS; Singapore General Hospital, 37581, Department of Respiratory and Critical Care Medicine, Singapore, Singapore., Kuna P; Medical University of Lodz, 37808, Division of Internal Medicine Asthma and Allergy, Lodz, Lodzkie, Poland., Larenas-Linnemann DES; Médica Sur Clinical Foundation and Hospital, Center of Excellence in Asthma and Allergy, Mexico City, Mexico., Lehtimäki L; University of Tampere, 7840, Immunopharmacology reserach group, Tampere, Pirkanmaa, Finland., Mahboub B; Rashid Hospital, 62743, Dubai, United Arab Emirates., Martin N; AstraZeneca R&D Cambridge, 468087, Respiratory and Immunology, BioPharmaceuticals Medical, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland.; University of Leicester, 4488, Leicester, Leicestershire, United Kingdom of Great Britain and Northern Ireland., Matsumoto H; Kindai University Faculty of Medicine, Department of Respiratory Medicine & Allergology, Osakasayama, Osaka, Japan., Menzies-Gow AN; AstraZeneca UK Limited, 4978, Cambridge, United Kingdom of Great Britain and Northern Ireland.; Royal Brompton and Harefield Hospitals, 4964, London, United Kingdom of Great Britain and Northern Ireland., Papadopoulos NG; University of Athens, Allergy Dpt, 2nd Pediatric Clinic, Athens, Greece.; University of Manchester, Centre for Paediatrics and Child Health, Institute of Human Development, Manchester, United Kingdom of Great Britain and Northern Ireland., Popov TA; Medical University Sofia, Clinic of Allergy & Asthma, Sofia, Bulgaria., Porsbjerg CM; Bispebjerg Hospital, 53166, Department of Respiratory Medicine, Copenhagen NV, Denmark.; University of Copenhagen, 4321, Institute of Clinical Medicine, Kobenhavn, Denmark., Patel P; Royal Brompton Hospital, 156726, London, United Kingdom of Great Britain and Northern Ireland., Rhee CK; Catholic university of Korea, Internal medicine, Seoul, Korea (the Republic of)., Sadatsafavi M; University of British Columbia, Institute for Heart and Lung Health, Vancouver, British Columbia, Canada., Taillé C; Inserm, Pathophysiology and Epidemiology of respiratory diseases. Epidemiology team, Paris, France.; Assistance Publique-Hôpitaux de Paris,, Paris, France., Torres-Duque CA; Fundación Neumológica Colombiana, Research Department, Bogotá, Colombia.; Universidad de La Sabana, 27989, Chia, Colombia., Tsai MJ; Kaohsiung Medical University Hospital, Kaohsiung Medical University, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung, Taiwan., Ulrik CS; Hvidovre Hospital, 53137, Respiratory Medicine, Hvidovre, Denmark.; University of Copenhagen, Institute of Clinical Medicine, Denmark., Upham JW; The University of Queensland, School of Medicine, Brisbane, Queensland, Australia., von Bülow A; Copenhagen University Hospital Bispebjerg, Department of Respiratory Medicine, Copenhagen, Denmark., Wang E; National Jewish Health, 2930, Division of Allergy and Clinical Immunology, Department of Medicine, Denver, Colorado, United States., Wechsler ME; National Jewish Health, Department of Medicine, Denver, Colorado, United States., Price DB; University of Aberdeen, Academic Primary Care, Aberdeen, Scotland, United Kingdom of Great Britain and Northern Ireland; dprice@opri.sg. |
| المصدر: | American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2024 May 03. Date of Electronic Publication: 2024 May 03. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Thoracic Society Country of Publication: United States NLM ID: 9421642 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-4970 (Electronic) Linking ISSN: 1073449X NLM ISO Abbreviation: Am J Respir Crit Care Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2000- : New York, NY : American Thoracic Society Original Publication: New York, NY : American Lung Association, c1994- |
| مستخلص: | Rationale: There is no consensus on criteria to include in an asthma remission definition in real-life. Factors associated with achieving remission post-biologic-initiation remain poorly understood. Objectives: To quantify the proportion of adults with severe asthma achieving multi-domain-defined remission post-biologic-initiation and identify pre-biologic characteristics associated with achieving remission which may be used to predict it. Methods: This was a longitudinal cohort study using data from 23 countries from the International Severe Asthma Registry. Four asthma outcome domains were assessed in the 1-year pre- and post-biologic-initiation. A priori -defined remission cut-offs were: 0 exacerbations/year, no long-term oral corticosteroid (LTOCS), partly/well-controlled asthma, and percent predicted forced expiratory volume in one second ≥80%. Remission was defined using 2 (exacerbations + LTOCS), 3 (+control or +lung function) and 4 of these domains. The association between pre-biologic characteristics and post-biologic remission was assessed by multivariable analysis. Measurements and Main Results: 50.2%, 33.5%, 25.8% and 20.3% of patients met criteria for 2, 3 (+control), 3 (+lung function) and 4-domain-remission, respectively. The odds of achieving 4-domain remission decreased by 15% for every additional 10-years asthma duration (odds ratio: 0.85; 95% CI: 0.73, 1.00). The odds of remission increased in those with fewer exacerbations/year, lower LTOCS daily dose, better control and better lung function pre-biologic-initiation. Conclusions: One in 5 patients achieved 4-domain remission within 1-year of biologic-initiation. Patients with less severe impairment and shorter asthma duration at initiation had a greater chance of achieving remission post-biologic, indicating that biologic treatment should not be delayed if remission is the goal. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| فهرسة مساهمة: | Keywords: anti-IL4Rα; anti-IL5/5R; anti-IgE; exacerbation; lung function |
| تواريخ الأحداث: | Date Created: 20240503 Latest Revision: 20240507 |
| رمز التحديث: | 20240507 |
| DOI: | 10.1164/rccm.202311-2192OC |
| PMID: | 38701495 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1535-4970 |
|---|---|
| DOI: | 10.1164/rccm.202311-2192OC |